Modified-Release Oral Minoxidil for Sustained Hair Loss Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for hair loss, particularly male and female pattern baldness, do not provide sustained and controlled release of minoxidil, leading to variable pharmacokinetic profiles and potential adverse effects.

Innovation Solution

A modified release formulation of minoxidil or its pharmaceutically acceptable salt, designed for oral administration, which releases 50% to 98% of the daily dose within 12 hours, with a Tmax of 30 to 360 minutes and Cmax of 0.25 ng/ml to 20 ng/ml, minimizing adverse effects and optimizing hair regrowth treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Speed

If immediate release formulation of minoxidil is used, then rapid onset of action is achieved, but adverse effects such as peripheral edema, tachycardia, and hypotension increase

Engineering Contradiction:

Improveonset of actionVSAvoidadverse effects

Core Design Contradiction:

SpeedVSObject-affected harmful factors

Solution Approach 1:

The patent applies dynamics by transitioning from static immediate-release to dynamic modified-release formulation that adapts drug delivery over time. The formulation releases minoxidil at varying rates - higher initially for rapid effect, then sustained at lower levels to maintain efficacy while reducing peak-related adverse effects.

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The modified-release formulation implements periodic action through controlled release phases. Instead of single-dose immediate release, the system provides periodic drug delivery over an extended period (12-24 hours), creating multiple lower peaks that achieve therapeutic effect while minimizing the magnitude of individual peaks that cause adverse effects.

Inventive Principle:

Principle #19Periodic action

2Reliability

If high dose minoxidil is administered to ensure therapeutic effect, then hair regrowth efficacy is improved, but adverse effects increase

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidadverse effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by modifying the release rate parameter of minoxidil over time. The formulation maintains adequate serum concentrations throughout the dosing interval rather than relying on high peak concentrations, achieving therapeutic efficacy through sustained exposure at optimized concentration levels that minimize adverse effects.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The modified-release formulation ensures continuity of useful action by providing sustained minoxidil release over 12-24 hours. This continuous delivery maintains therapeutic serum concentrations throughout the dosing interval, ensuring reliable hair regrowth efficacy without the fluctuations that lead to adverse effects from intermittent high-dose administration.

Inventive Principle:

Principle #20Continuity of useful action

3Duration of action of moving object

If multiple daily doses are administered to maintain serum concentrations, then therapeutic effect is sustained, but patient compliance and treatment complexity increase

Engineering Contradiction:

Improveduration of therapeutic effectVSAvoidpatient compliance

Core Design Contradiction:

Duration of action of moving objectVSEase of operation

Solution Approach 1:

The patent applies preliminary action by formulating minoxidil in a modified-release dosage form that pre-programmes the release profile. This preliminary formulation work ensures sustained drug delivery over 12-24 hours from a single dose, eliminating the need for multiple daily administrations and significantly improving patient compliance while maintaining therapeutic efficacy.

Inventive Principle:

Principle #10Preliminary action

4Object-affected harmful factors

If modified release formulation is designed to extend release duration, then adverse effects are reduced, but manufacturing precision requirements increase

Engineering Contradiction:

Improveadverse effectsVSAvoidrelease profile control

Core Design Contradiction:

Object-affected harmful factorsVSManufacturing precision

Solution Approach 1:

The patent applies local quality by incorporating specific release-modifying excipients into the minoxidil formulation matrix. These excipients create localized properties within the dosage form that control drug release kinetics, enabling sustained release over 12-24 hours while managing manufacturing precision requirements through established pharmaceutical formulation techniques.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS20260097035A1Compositions and methods of use for modified release minoxidil

Publication Date: 2026.04.09 VERADERMICS INC

AI summary

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.